3
2
1

New Breakthrough in Oocyte Cryopreservation: Magnetically Controlled Hydrogel + Microfluidics Significantly Boosts Survival Rates

Release time:

2026-08-28

In the field of assisted reproductive medicine, cryopreservation of oocytes (immature egg cells) is a key technology—not only critical for fertility preservation in infertile patients, but also playing an important role in the conservation of rare animal species. However, this technology has long faced two major challenges: osmotic injury caused by high concentrations of cryoprotectants, and cell death resulting from ice crystal formation during the rewarming process.

The Limitations of Conventional Techniques

The currently most widely used method, vitrification, achieves ultra‑rapid cooling to transform the intracellular environment into a glass‑like amorphous state, thereby avoiding ice crystal damage. Yet the problem is that the high concentrations of cryoprotectants required for vitrification induce severe osmotic shocks during both loading and unloading, placing substantial stress on oocytes. Moreover, the rewarming phase still carries the risk of ice formation and recrystallization. Although existing microfluidic technologies can generate continuous concentration gradients to alleviate osmotic damage, they are generally hampered by low cell loading/recovery efficiency and complex operation, limiting their practical application.

 

An Innovative Strategy: Combining Two Approaches

To address these challenges, a collaborative team led by Professor Chen Zhongrong from Anhui Medical University, Professor Zhao Gang from the University of Science and Technology of China, and Professor Cheng Yue from Anhui Medical University proposed an innovative solution—integrating a microfluidic chip with magnetically controlled hydrogel microencapsulation technology. This research has been published in the internationally renowned journal Biomaterials.

The core innovation of this technology lies in embedding magnetic beads into an alginate hydrogel matrix to form microcapsules, within which oocytes are encapsulated. In this way, researchers can precisely manipulate the position of oocytes in the microchannels using an external magnetic field, eliminating the need for complex trapping structures. This not only simplifies chip design but also prevents cell drift and loss. At the same time, the hydrogel matrix provides a physical protective barrier for the oocytes.

On the microfluidic chip front, the team custom‑designed a chip with a rapid‑sealing lid, enabling linear loading of cryoprotectants—where the concentration changes gradually rather than abruptly—thereby minimizing osmotic damage to the greatest extent.

 

Encouraging Data

Experimental results demonstrate that, compared with the conventional straw‑based vitrification method, the new strategy significantly increased the survival rate of mouse oocytes from 57.47% to 86.63%—a remarkable improvement.

Furthermore, the study validated oocyte quality across multiple dimensions: post‑rewarming oocytes showed better preservation of mitochondrial activity and cytoskeletal structure. More importantly, subsequent embryo development experiments revealed that the fertilization rate and cleavage rate of these oocytes were also significantly superior to those of the control group, indicating that their developmental potential was effectively safeguarded.

 

Promising Clinical Translation Prospects

From a technical standpoint, the combination of magnetic manipulation and an open‑closed microfluidic chip greatly simplifies operational procedures and chip architecture, overcoming the practical difficulties of traditional methods and establishing a highly controllable and easy‑to‑implement new approach.

The research team noted that, compared with the current clinical vitrification standard, this method achieves comparable survival rates, yet its unique advantage lies in better preserving the physiological integrity and subsequent developmental competence of oocytes. This offers a new option with significant translational potential for oocyte cryopreservation in assisted reproductive medicine, and is expected to benefit more patients with fertility preservation needs in the future.

Latest developments

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.